Perrigo Q2 net sales fall 0.9% to $1.06 billion; adjusted EPS rises to $0.57
Perrigo reported second-quarter 2025 results for the period ended June 28, 2025, with net sales of $1.06 billion, down 0.9% year over year, and adjusted diluted EPS of $0.57, up 7.5%. The company reaffirmed its full-year 2025 adjusted EPS target of $2.90 to $3.10 but now expects reported and organic net sales growth toward the lower end of its ranges, citing infant formula recovery that is slower than anticipated and weak market consumption.
Key points
- Net sales were $1.06 billion, down 0.9%, with divestitures and exited products reducing sales by 2.5% and currency adding 1.7%.
- Reported diluted EPS was $0.00 versus a loss of $(0.77) a year earlier; adjusted diluted EPS was $0.57 versus $0.53.
- Full-year 2025 outlook: reported net sales growth of 0% to 3%, adjusted diluted EPS of $2.90 to $3.10, with net sales expected toward the lower end of the ranges.
- The Dermacosmetics business sale is expected to close in the first quarter of 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.